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Abstract 
Understanding blood-brain barrier function under physiological and pathophysiological conditions is critical for the development of new 
therapeutic strategies that hold the promise to enhance brain drug delivery, improve brain protection, and treat brain disorders. However, 
studying the human blood-brain barrier function is challenging. Thus, there is a critical need for appropriate models. In this regard, brain 
capillaries isolated from human brain tissue represent a unique tool to study barrier function as close to the human in vivo situation as possible. 
Here, we describe an optimized protocol to isolate capillaries from human brain tissue at a high yield and with consistent quality and purity. 
Capillaries are isolated from fresh human brain tissue using mechanical homogenization, density-gradient centrifugation, and filtration. After 
the isolation, the human brain capillaries can be used for various applications including leakage assays, live cell imaging, and immune-based 
assays to study protein expression and function, enzyme activity, or intracellular signaling. Isolated human brain capillaries are a unique 
model to elucidate the regulation of the human blood-brain barrier function. This model can provide insights into central nervous system (CNS) 
pathogenesis, which will help the development of therapeutic strategies for treating CNS disorders. 
Video Link 
The video component of this article can be found at https://www.jove.com/video/57346/ 
Introduction 
The blood-brain barrier is a tightly controlled interface between the blood and brain that determines what goes into and comes out of the 
brain. Anatomically, endothelial cells compose the blood-brain barrier and forms a complex, continuous capillary network. Physiologically, this 
capillary network supplies the brain with oxygen and nutrients while simultaneously disposing of carbon dioxide and metabolic waste products. 
Importantly, evidence supports that the changes to the barrier contribute to numerous pathologies, including Alzheimer's disease, epilepsy, 
and stroke 1 ·2·3·4·5·5·7 _ Brain endothelial cells also serve as a barrier to treatment by blocking drug uptake into the brain, e.g., chemotherapy 
of glioblastoma multiforme following tumor resection8·9·10_ In this regard, isolated human brain capillaries represent a unique ex vivo blood-
brain barrier model that closely resembles barrier properties in vivo, which allows for the study of barrier function and dysfunction in health and 
disease. In this article, we provide a protocol to isolate brain capillaries from human brain at a consistently high capillary quality and yield to study 
the blood-brain barrier. 
In 1969, Siakotos et a/. 11 were the first to report the isolation of brain capillaries from bovine and human brain tissue using density gradient 
centrifugation and glass bead column separation. Later, Goldstein et a/. 12 improved this method by adding multiple filtration steps to decrease 
the amount of tissue needed to study brain capillaries isolated from rats, while maintaining the metabolic activity of glucose transport. Since 
then, researchers optimized the capillary isolation procedure numerous times, improving the method and brain capillary model with each 
iteration 13·14·15. For example, Pardridge et a/. 16 isolated bovine capillaries using enzymatic digestion rather than mechanical homogenization, 
and then subsequently passed a capillary suspension through a 21 O µm mesh filter and a glass bead column. These modifications improved the 
trypan blue exclusion stain of isolated brain capillaries, and thus, increased endothelial cell viability. In the early 1990s, Dallaire et a/. 1 isolated 
bovine and rat capillaries that were clear of neuronal contamination and maintained metabolic activity of y-glutamyl transpeptidase (y-GTase) 
and alkaline phosphatase. In 2000, Miller et a/. 18 , used isolated rat and porcine brain capillaries in combination with confocal microscopy to 
show the accumulation of transport substrates into the lumen of capillaries. Subsequently, our laboratory has continued to optimize the brain 
capillary isolation gocedure and we have established transport assays to determine P-glycoprotein (P-gp) 19·20·21 , breast cancer resistance 
protein (BCRP)22· 3 , and multi-drug resistance protein 2 (Mrp2)24 transport activity. In 2004, we published two reports where we used isolated rat 
brain capillaries to investigate various signaling pathways. In Hartz et a/. 21 , we found that the peptide endothelin-1 rapidly and reversibly reduced 
P-gp transport function in brain capillaries by acting through the endothelin receptor B (ET 8) receptor, nitric oxide synthase (NOS), and protein 
kinase C (PKC). In Bauer et al. 19, we demonstrated expression of the nuclear receptor pregnane X receptor (PXR) and showed PXR-modulation 
of P-gp expression and transport function in brain capillaries. In experiments with transgenic humanized PXR mice, we expanded this line of 
research and showed in vivo tightening of the barrier by upregulating P-gp through hPXR activation25 . In 2010, Hartz et a/. 26 used this approach 
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to restore P-gp protein expression and transport activity in transgenic human amyloid precursor protein (hAPP) mice that overexpress hAPP. 
Moreover, restoring P-gp in hAPP mice significantly reduced amyloid beta (Af3)40and A[342brain levels. 
In addition to studying signaling pathways, isolated brain capillaries can be used to determine changes in capillary permeability which we refer 
to as capillary leakage. In particular, the Texas Red leakage assay is used to assess leakage of the fluorescent dye Texas Red from the capillary 
lumen over time and these data are then used to analyze leakage rates. Increased capillary leakage rates compared to those from control 
capillaries indicate changes in the physical integrity of the blood-brain barrier2. This is valuable because there are numerous disease states 
associated with barrier disruption, e.g., epilepsy, multiple sclerosis, Alzheimer's disease, and traumatic brain injury27·28·29·30 . Other groups have 
also utilized isolated capillaries to discern signaling pathways that regulate protein expression and transport activity of proteins31 ·32·33·34·35·36·37 . 
Finally, we have continued to optimize this method for the isolation of human brain capillaries and, recently, we showed increased P-gp 
expression at the human blood-brain barrier in patients with epilepsy compared to seizure-free control individuals38 . Taken together, these 
developments demonstrate that isolated brain capillaries can serve as a versatile model to study barrier function. 
Various in vivo, ex vivo, and in vitro blood-brain barrier models have been used in basic research and industrial drug screening, mainly with the 
goal of testing drug delivery to the brain39·40·41 ·42·43·44 . In addition to isolated ex vivo brain capillaries, current blood-brain barrier models include 
in silica models, in vitro cell culture of isolated brain capillary endothelial cells or immortalized cell lines from various species, in vitro culture of 
human pluripotent stem cells (hPSC) that differentiate into brain capillary endothelial cells, and microfluidic models on a chip. 
In silica models are most commonly used in drug development for selecting drug candidates based on predicted absorption, distribution, 
metabolism, and excretion (ADME) properties. Methods such as quantitative structure-property relationship (QSPR) models and quantitative 
structure-activity relationship (QSAR) models are popular methods used in high-throughput screening of libraries to predict brain penetration of 
drug candidates45·46 . These models are useful to screen molecules for barrier penetration properties. 
Betz et al. 47 established monolayers of cultured brain capillary endothelial cells as an in vitro blood-brain barrier model system. In vitro cell 
culture models using fresh tissue or immortalized endothelial cell lines such as human cerebral microvessel endothelial cells (hCMECs) can 
be another high-throughput screening tool for brain penetration or mechanistic studies. However, brain capillary endothelial cell culture models 
lack the physiologic shear stress of blood flow inside the capillary lumen, are limited in overall biologic complexity, and undergo changes in 
expression and localization of important barrier components such as tight junction proteins, surface receptors, transporters, enzymes, and ion 
channels48·49·50 . Conversely, endothelial monolayers derived from hPSCs, have low sucrose permeability compared to hCMEC/03 cultures and 
contain polarized expression of some blood-brain barrier transporters, adhesion molecules, and tight junctions51 ·52 . However, these cells are also 
subject to changing properties in the culture, and the system must be validated for its recapitulation of in vivo barrier properties52 . 
Newer trends in blood-brain barrier research include utilizing 30 tissue culture systems to create artificial capillaries, using the organ-on-chip 
technology to generate microfluidic devices, or utilizing the hollow fiber technology53·54·55 . Artificial capillaries, however, have significantly larger 
diameters (100-200 µm) than brain capillaries (3-7 µm). Hence, the shear forces in vitro do not fully resemble the in vivo situation. This is 
addressed in "blood-brain-barrier-on-a-chip" microfluidic devices, where artificial membranes form "blood" and "brain" compartments and fluids 
are pumped through these devices generating microfluidic shear forces. Similarly, co-cultures of endothelial cells in various combinations with 
astrocytes and vascular smooth muscle cells have also been used with the hollow fiber technology to recreate rheological parameters present 
under in vivo conditions56·57·58 . However, it is unclear how well this model reflects other properties of the blood-brain barrier such as transport, 
metabolism, signaling, and others. These artificial capillary and chip models are suitable for high-throughput screening of drugs, but the cells 
used to generate these models are also subject to change during culture. 
Frozen and fixed brain slices or primary brain capillary endothelial cell cultures are additional models that can be used tostudy the human 
microvasculature5·59·60 ·61 . For example, immunohistochemistry of fixed brain tissue is used to determine protein localization and expression in 
healthy compared to diseased tissue. 
In addition to tissue slices and the in vitro models described above, freshly isolated brain capillaries can be utilized to study blood-brain barrier 
function. Limitations of this isolated capillary model include the difficulty to obtain fresh human brain tissue, absence of astrocytes and neurons, 
and a relatively time-consuming isolation process. An advantage of the isolated brain capillary model is that this model closely resembles the in 
vivo situation and, therefore, can be used to characterize barrier function and dysfunction. Importantly, it can also be used to discern signaling 
mechanisms using a multitude of assays and molecular techniques3·19·62·63 . 
Our laboratory has access to both fresh and frozen human brain tissue through the Sanders-Brown Center on Aging (IRB #815-2602-M)64 . In 
this context, autopsies follow a standard protocol, brains are obtained in <4 h, and all procedures conform to NIH Biospecimen Best Practice 
Guidelines65 . Given this unique access to human brain tissue, we established and optimized a protocol to isolate brain capillaries from human 
brain tissue that results in a high yield of intact, viable human brain capillaries. Two common endpoints of interest are to determine the protein 
expression and activity. In this regard, we and others have established various assays that can be used with isolated brain capillaries to study 
protein expression and activity levels. These assays include Western blotting, Simple Western assay, enzyme-linked immunosorbent assay 
(ELISA), reverse transcription polymerase chain reaction (RT-PCR), quantitative polymerase chain reaction (qPCR), zymography, transport 
activity assays, and capillary leakage assays. These assays allow researchers to study changes in barrier function in human pathologic 
conditions, determine pathways that govern protein expression and activity, and identify pharmacologic targets for the treatment of blood-brain 
barrier associated diseases. 
Taken together, freshly isolated brain capillaries can serve as a robust and reproducible model of the blood-brain barrier. Especially, this model 
can be combined with many different assays to determine a wide array of endpoints to study barrier function. 
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Protocol 
The information below is based on current safety and regulatory standards at the University of Kentucky, Lexington, KY, USA. As a safety 
precaution, refer to the institution's biological safety program and the most current regulations and recommendations before working with human 
tissue. 
CAUTION: Human tissue can be a source of blood-borne pathogens, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), 
hepatitis C virus (HCV), and others. Working with human tissue poses the risk of infection from blood-borne pathogens. Therefore, certain 
regulatory and safety considerations are imperative when working with human tissue to protect laboratory personnel. Working with human tissue 
in the US requires a biosafety level 2 laboratory as well as safety precautions and training in accordance with NIH Section IV-B-7, OSHA Act 
of 1970 Clause 5(a)(1) and the user's institutional biological safety program. In general, Institutional Biosafety Committee and/or Institutional 
Review Board approval must be obtained prior to conducting any research involving human materials (tissue, body fluids). The training is 
required for all personnel working with human materials and includes basic laboratory safety training, e.g., Chemical Hygiene and Laboratory 
Safety, as well as specific training on biological safety, hazardous waste, and human blood-borne pathogens. All personnel working with human 
materials are highly recommended to obtain Hepatitis B vaccinations, prior to working with human materials. Personnel are required to wear 
specific personal protective equipment while working with human materials, e.g., a cuffed lab coat and a face shield, and wear gloves at all times. 
All work is performed in a biosafety cabinet (class 2). All equipment that comes in contact with human materials and any waste from human 
materials is handled appropriately to prevent contamination and/or infection of personnel. All equipment and surfaces are cleaned with 10% 
bleach and 75% ethanol following each procedure involving human materials. A spill with human materials must be immediately cleaned up. 
Glassware is autoclaved after each use. Waste, including unfixed human tissue, is collected in a labeled biohazard waste bag and autoclaved. 
Sharps are collected in a puncture- and leak-proof container labeled as biohazardous. All waste from human materials is disposed according to 
the institution's biological safety regulations. 
NOTE: Our laboratory obtains fresh frontal cortex samples from deceased individuals through the Sanders-Brown Center on Aging (IRB 
#815-2602-M). Inclusion criteria are: enrollment in the UK-ADC longitudinal autopsy cohort study and a Post-Mortem Interval (PMI) :54 h64 . 
Autopsies follow a standard protocol and all procedures conform to NIH Biospecimen Best Practice Guidelines65 . A short PMI of less than 4 h 
is of highest importance to ensure capillary viability after isolation. Both fresh and frozen tissue can be used. If freezing is necessary, freshly 
obtained human brain tissue should be shock-frozen in liquid nitrogen and stored at -80 °C. Fresh or thawed tissue should be stored in isolation 
buffer (see below) and processed quickly. We find that 1 O g of fresh human tissue yields about 100 mg of brain capillaries (wet weight). 
1. Setup 
1 . Buffer preparation 
NOTE: The volume of buffer needed depends on the amount of tissue. All buffer volumes in the following protocol are based on 1 O g of 
human brain cortex tissue. 
1. L Isolation Buffer: Use 1.5 L of Dulbecco's phosphate-buffered saline (DPBS; 2. 7 mM KCI, 1.47 mM KH2P04, 136. 9 mM NaCl, 8.1 mM 
Na2HP04, 0.9 mM CaCl2 , 0.49 mM MgCl2) and supplement with 5 mM D-glucose (1.35 g) and 1 mM sodium pyruvate (0.165 g). After 
adding the glucose and pyruvate, adjust to pH 7.4 with sodium hydroxide. Cool and store the buffer to 4 °C prior to use. 
2. Bovine Serum Albumin (BSA): Add 1 O g of BSA powder to 1 L of isolation buffer to a final BSA concentration of 1 %. Stir slowly to avoid 
bubbles, adjust to pH 7.4, and store at 4 °C overnight. Immediately prior to use, gently stir; avoid forming bubbles to avoid albumin 
denaturation. 
3. density gradient medium: Weigh 18 g of density gradient medium into a glass bottle and add a magnetic stir bar. Add 60 ml of isolation 
buffer and shake vigorously for 5 min until all powder is suspended. Store overnight at 4 °C to allow the density gradient medium to 
dissolve. Stir for 1 O min right before use. 
4. Store all buffers at 4 °C; keep all tools and buffers on ice during the entire isolation procedure. Stir all buffers before use. 
2. Experimental setup 
1. Mount the pestle of the Potter-Elvehjem tissue grinder onto the electronic overhead stirrer. Place the Potter-Elvehjem tissue grinder 
and the Dounce homogenizer with pestle on ice under the hood. Prepare a 300 µm filter mesh (5 x 5 cm\ fold it to a cone, and insert 
and attach it to a 50 ml Falcon tube with tape (Figure 1A). 
2. Place connecting rings and cell strain filters (pore size: 30 µm) on 50 ml Falcon tubes. Prepare biohazardous waste bags. Place all 
required equipment in the biosafety cabinet (see Table of Materials). 
2. Brain Sample Preparation 
NOTE: Figure 1A shows the workflow chart of the entire isolation procedure described below. Human brain tissue can stem from any part of 
the cortex and can be used fresh or frozen. Frozen brain tissue can be thawed at room temperature (no buffer; -30 min for 1 O g). To achieve 
comparable results, the brain tissue should be obtained from the same brain region for each experiment. This protocol is optimized for fresh (PMI 
<4 h) human cerebral cortex that has not been frozen. 
1. Preparation of human brain tissue: Document the weight of the brain tissue. All numbers in the following protocol are appropriate for 1 O g of 
fresh human brain tissue. Place the brain tissue in a 100 mm Petri dish. Carefully remove all the meninges with forceps. Use a scalpel to cut 
off the white matter. 
2. Mincing of the human brain tissue: Carefully cut up the brain tissue and mince it with a scalpel. Mince for about 5 min (2-3 mm pieces). 
Transfer the brain tissue to the Potter-Elvehjem tissue grinder. Add 30 ml of isolation buffer. 
NOTE: The minced tissue pieces are difficult to see since the brain tissue turns into mush through the mincing process. 
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3. Homogenization 
1. Potter-Elvehjem tissue grinder (clearance: 150-230 µm): Homogenize each sample with 100 strokes at a homogenizer speed of 50 rpm. 
Document the time every 25 strokes and the total time needed for 100 strokes. See Table 1 for a proposed homogenization protocol; the total 
time for homogenizing 1 O g of human frontal cortex is about 22 min. Do not stir in air to prevent bubbles. 
2. Dounce homogenizer (clearance: 80-130 µm): Transfer the homogenate to a Dounce homogenizer on ice. Homogenize the suspension with 
20 strokes (-6 s/stroke, total of -2 min). Avoid bubbles. 
4. Centrifugation 
1. Distribute the brain homogenate equally into four 50 ml centrifugation tubes and document the total volume of the homogenate. Distribute 
50 ml of density gradient buffer into the centrifugation tubes (12.5 ml per tube). Use 1 O ml of isolation buffer to rinse the pestle and 
homogenizer, and distribute into the four centrifugation tubes (-2.5 ml per tube). 
2. Tightly close the centrifuge tubes with caps. Mix the homogenate, density gradient medium, and buffer by vigorously shaking the tubes. 
Centrifuge at 5,800 x g for 15 min at 4 °C (fixed angle rotor); select a medium deceleration speed to keep the pellet attached to the tube. 
Discard the supernatant and resuspend each pellet in 2 ml of 1 % BSA. 
5. Filtration 
NOTE: To separate the capillaries from red blood cells and other cell debris, several filtration steps are necessary. 
1. 300 µm mesh: After re-suspending the pellet, filter the suspension through the 300 µm mesh. Capillaries are filtered through the mesh, 
whereas larger vessels and larger brain debris remain on the mesh. Carefully wash the mesh with up to 50 ml of 1 % BSA. Discard the mesh. 
NOTE: This filtration step clears the capillary suspension from any larger vessels or chunks of brain debris. 
2. 30 µM cell strain filter 
NOTE: This filtration step separates capillaries from red blood cells and other brain debris. 
1. Distribute the capillary filtrate from step 6.1 over the five 30 µm cell strain filters (about 1 O ml of capillary filtrate per cell strain filter). 
Capillaries are held back by this filter, whereas red blood cells, other single cells, and small brain debris pass through the filter and are 
collected in the filtrate. 
2. Wash each filter with 25 ml of 1 % BSA. Afterwards, pour all filtrates over the sixth filter to increase the yield. Wash each filter with 50 
ml of 1 % BSA; keep the cell strain filters with containing the capillaries and discard the filtrate. 
6. Capillary Collection 
1. Turn the filters upside down and wash the capillaries with 50 ml of 1 % BSA for each filter into 50 ml tubes. Gently apply pressure with the 
pipet tip of a 5 ml pipettor and move it across the filter to wash off the brain capillaries. 
2. Make sure to wash off all brain capillaries, especially from the rim of the filter. Avoid bubbles since this makes the filtration process more 
difficult and increases the chance of capillary loss. 
7. Washing 
1. After collecting the capillaries, centrifuge all samples at 1,500 x g for 3 min at 4 °C (swinging bucket rotor). Remove the supernatant and re-
suspend the pellet in approximately 3 ml of isolation buffer. Combine all resuspended pellets from one sample in a 15 ml conical tube and fill 
it with isolation buffer. Centrifuge again at 1,500 x g for 3 min at 4 °C and wash two more times. 
2. Document the capillary purity with a microscope (1 OOX magnification) and camera (Figure 1 B). 
NOTE: The brain capillary yield from 1 O g of human brain tissue is usually about 100 mg. The isolated brain capillaries can now be used 
for experiments, processed (e.g., lysate, membrane isolation), or be flash-frozen and stored at -80 °C in cryotubes for a minimum of 6-12 
months (avoid multiple freeze-thaw cycles). 
Representative Results 
The isolations from human brain tissue yield a suspension enriched in human brain capillaries (Figure 1 B) with small amounts of larger vessels, 
red blood cells, other single cells, and some cell debris. Some capillaries are branched, and, in some, red blood cells are entrapped in the 
capillary lumens. The typical capillary has a 3-7 µm diameter and is approximately 100-200 µm long with open lumens; most capillary ends are 
collapsed. Using confocal microscopy, isolated human brain capillaries reveal a tubular, intact structure and morphology. Figure 2A shows a 
representative transmitted light image of a human brain capillary with an attached pericyte and a red blood cell in the lumen. All of the findings 
regarding diameter, size, and morphology are in accordance with previous reports on the structure of isolated brain capillaries 12·17·18. The 
isolated human brain capillary in Figure 28 was immunostained for P-gp (green) using C219 as the primary antibody (1 µg/ml); nuclei were 
counterstained with DAPI (1 µg/ml). 
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Figure 1: Flowchart for capillary isolation. (A) The pictogram illustrates major steps of the procedure to isolate brain capillaries from fresh 
human tissue. (B) The picture shows isolated human brain capillaries under a light microscope directly after isolation (1 OOX magnification). 
Please click here to view a larger version of this figure. 
A B 
Figure 2: Isolated human brain capillary. (A) A transmitted light image of an isolated human brain capillary. (B) The confocal microscope 
image shows an isolated human brain capillary immunostained for P-gp (green; C219 1 µg/ml); nuclei were counterstained with DAPI (blue; 1 
µg/ml). Please click here to view a larger version of this figure. 
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Figure 3: Troubleshooting density centrifugation. The pictogram shows the preparation after the density gradient centrifugation. It highlights 
the effects of too much and too little density gradient medium and how this affects the separation and the resulting capillary pellet. Please click 
here to view a larger version of this figure. 
P-gp 182 kDa 
P-Actin 42 kDa 
15 1.5 
Protein [µg] 
Figure 4: P-gp protein expression in isolated human brain capillaries. The Western blot shows strong bands for P-gp (1 µg/ml) in isolated 
human capillaries compared to hCMEC\03 cells. 13-Actin was used as a loading control (1 µg/µL). Please click here to view a larger version of 
this figure. 
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Figure 5: Applications for isolated human brain capillaries. An overview of the most common applications for isolated brain capillaries 
published in the literature. Isolated capillaries have been used for: 1) Genomics85·86 , 2) Proteomics3·38·87·88·89·90·91 ·92·94·95·96 , 3) Functional 
Proteomics2·38 , and 4) Cellomics82·83·84·97·98·99 . Please click here to view a larger version of this figure. 
Strokes Time [min] 
1-25 7-7.5 
26-50 5-5.5 
51-75 5-5.5 
76-100 5-5.5 
Total Time: 22-24 min 
Table 1: Homogenization protocol. The homogenization protocol for the Potter-Elvehjem tissue grinder to homogenize 1 O g of human frontal 
cortex at a homogenization speed of 50 rpm. Note that the first several strokes require additional time to homogenize the minced tissue. After 
this initial homogenization, each stroke is 12 s in duration (6 s for downward movement, 6 s for upward movement). Thus, after the initial 
homogenization, 5 strokes can be accomplished in 1 min, or 25 strokes in 5 min. 
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Problem Potential Cause Solution 
No Capillary Pellet 1) Incorrect Ficoll concentration 1) Adjust Ficoll concentration 
2) Incorrect centrifugation speed 2) Adjust centrifugation speed 
3) Incorrect acceleration and/or deceleration 3) Adjust acceleration and/or deceleration 
speed speed 
Low Capillary Yield 1) Meninges blocking filtration steps 1) Remove ALL meninges prior to filtration 
2) Too many capillaries lost during isolation 2) Calculate buffer concentration correctly, 
procedure rinse pipette tips 
3) Washing capillaries off PluriStrainer filters 3) Turn filters over and carefully inspect for 
was insufficient capillaries (use microscope) 
4) Excess bubbles during resuspensions 4) Pipette slowly to avoid bubbles 
Non-Viable Capillaries 1) Extended post-mortem interval 1) Reduce interval if possible or use snap-
frozen brains 
2) Using frozen tissue for the isolation 2) Use fresh tissue 
3) Time of isolation procedure too long 3) Optimize workflow 
4) EquipmenUbuffers were not kept on ice 4) Keep equipment and buffers on ice during 
during the isolation procedure the isolation 
Table 2: Troubleshooting of common problems. A list of the most common errors and problems that occur during the isolation procedure and 
how they can be resolved. 
Discussion 
The present protocol describes the isolation of intact and viable human brain capillaries from fresh tissue. In this section, we discuss in detail the 
following: 1) modifications to the protocol, 2) troubleshooting of common errors, 3) limitations of the technique, 4) the significance of the model 
with respect to existing and alternative blood-brain barrier models, and 5) potential applications for isolated human brain capillaries. 
The protocol described here is optimized for 1 O g of fresh human frontal cortex tissue. However, it is relatively simple to modify this procedure 
for: 1) more or less than 1 O g of tissue, 2) frozen brain tissue, or 3) brain tissue from a brain region other than the frontal cortex. First, with more 
or less than 1 O g of brain tissue, the necessary volume of the buffers can simply be scaled up or down to the available amount of tissue. Thus, 
if only 5 g of brain tissue is available, the volume of the buffers should be reduced by half. Second, we describe a capillary isolation that used 
fresh brain tissue, but frozen tissue may be used if fresh tissue is unavailable 38 . Third, we used fresh brain tissue taken from the frontal cortex, 
but capillaries may be isolated from other cortical brain regions if there is enough available tissue. It is also possible to isolate capillaries from 
non-cortical brain regions (e.g., white matter), but these regions have a different cell composition and capillary density 66·67·68 . Thus, using tissue 
from a different brain region would likely require the protocol to be adjusted (e.g., buffer volume, gradient medium density, centrifugation speed, 
and/or number of filtration steps). 
The capillary isolation procedure, while not complex per se, is sensitive to small perturbations or alterations in the protocol. Modifications 
may result in a diminished capillary yield or reduced capillary viability. Table 2 outlines the most common errors and problems that are 
encountered during the isolation and lists tips to avoid these errors and solutions for troubleshooting if they occur. The most common problem 
associated with the procedure is a low capillary yield. The loss of capillaries is often the cumulative sum of small losses at each step and is 
due to small deviations across the procedure. A critical step in which a large amount of capillaries may be lost is the density centrifugation. An 
incorrect concentration in the buffer results in an incorrect density to separate the capillaries from cellular debris that reduces the volume of 
the capillary pellet. Figure 3 shows the consequences of too little or too much density gradient medium in the centrifugation step relative to 
brain homogenate. Adjusting to the correct the concentration may solve this problem. Note that the acceleration and deceleration speed of the 
centrifuge can also affect the formation of the brain capillary pellet. Capillaries may also be lost during steps 6-7 if part of the capillary material 
sticks to the pipette tips. This issue can be addressed by thoroughly rinsing each pipet tip before changing it. During step 7, washing off the 
capillaries from the cell strain filter may be incomplete and/or capillaries may stick to the rim of the filter. This can be avoided by checking the 
filter under the microscope followed by additional washing steps. Losing capillaries during each step of the isolation procedure can result in a 
negligible capillary pellet or not enough capillary material for further processing and experimentation. 
Isolating brain capillaries from fresh human tissue represents a unique blood-brain barrier model that closely resembles the in vivo situation. 
However, several limitations of the technique exist. One challenge is the availability of fresh human tissue. As the optimal PMI is :54 h, brain 
tissue collected at a significantly longer PMI will not be fresh enough for some downstream applications. In some cases, it may be difficult to 
obtain tissue amounts that are large enough for multiple experimental groups, thereby restricting downstream applications. Thus, isolating 
fresh capillaries from rodent 19 , canine69 , bovine 42, or porcine70 brain tissue may be more suitable to model the blood-brain barrier. Factors that 
determine the variability of human brain tissue such as age, sex, ethnicity, disease state, medication history, brain region of sample, and PMI 
should be taken into consideration when interpreting and publishing data. On an experimental level it is important to note that isolated capillaries 
still include pericytes, but astrocytic endfeet are removed by the procedure 44. It needs to be taken into consideration that the model presented 
here serves as an ex vivo model of the blood-brain barrier (i.e., capillary endothelial cells) but not as a model of the neurovascular unit. 
Working with any human tissue always presents an inherent safety risk and researchers must take appropriate precautions during the isolation 
procedure to avoid infection. Specifically, in the U.S., work with human tissue requires designated laboratory space that is BSL 2-certified and 
includes a biosafety cabinet (class A2). In addition, staff must use personal protective equipment (i.e., lab coat, gloves, and face shield) and 
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designated equipment for work with human tissue and implement biohazardous waste handling. Implementing these safety measures is time-
consuming, cost-intensive, and increases the difficulty of the procedure, especially for inexperienced laboratory personnel. 
The blood-brain barrier is highly conserved among organisms with a well-defined CNS71 . Modeling the human blood-brain barrier is difficult 
because there is complex neurovascular coupling among the cells of the neurovascular unit. An adult human brain has been estimated to have 
in average about 86 billion neurons and it is thought that almost every neuron has its own capillary in the vicinity to ensure proper supply with 
oxygen and nutrients 72 ·73_ Capillary endothelial cells constitute the largest surface area of the blood-brain interface (12-18 m2 for a healthy 
adult human). Tight junctions represent an impediment to a wide array of pharmacotherapeutics by blocking paracellular diffusion of solutes. 
In addition, numerous studies describe barrier d¥5function in neurodegenerative disorders, e.g., Alzheimer's disease 74, stroke 75 , epilepsy38·76 , 
multiple sclerosis 77, and traumatic brain injury28· 8 . Thus, it is imperative to establish models that closely represent the human blood-brain barrier 
and allow for a better understanding of barrier function in health and disease. 
Numerous in vitro cell culture models of the blood-brain barrier exist; for expert reviews on the subject see 41 ·49·51 ·69·79·80 . Briefly, both freshly 
isolated brain capillary endothelial cells for primary culture and immortalized brain capillary endothelial cell lines are available. Primary cultures 
of cerebral microvessel endothelial cells are mostly used from mouse, rat, pig, and cow. However, primary cell cultures are labor-intensive 
since cells must be freshly isolated. Immortalized brain capillary endothelial cell lines are available from mouse, rat, and human and are less 
labor-intensive because they can be passaged for longer-term use. However, even immortalized cell lines have a limit on how often they can 
be passaged before losing their endothelial characteristics. Both primary cells as well as immortalized cells lines are often cultured on plates 
to model the brain capilla7 endothelium and measure the barrier permeability and drug transport across the cell monolayer, thereby mimicking 
blood-to-brain transport41 · 1·82 . The culture media in these models may also be modified or supplemented with astrocytes, pericytes, or other 
physiologically relevant factors like cAMP41 ·83·84 . 
The advantage of immortalized cell lines is their relatively easy access and availability. While cultured endothelial cells can reach confluence, 
they lose endothelial cell properties as they grow side-by-side in a monolayer. For example, cultured hCMECs display reduced expression of 
transporters like P-gp, tight junction proteins, and display variable permeability to xenobiotics41 . Figure 4 shows a Western blot for P-gp protein 
expression in hCMEC/D3 cells compared to freshly isolated human capillaries. Despite a 10-fold lower amount of total protein, the signal for P-
gp is stronger in isolated human capillaries compared to hCMEC/D3 cells. This indicates that hCMEC/D3 cells lost a significant amount of P-gp 
protein expression in culture. Moreover, differences in culture media, environment, and equipment affect key measures of barrier integrity, i.e., 
TEER measurements in Transwell plate assays. Some of these issues can be overcome by utilizing the isolated brain capillary model that more 
closely represents the human blood-brain barrier in vivo. 
Isolated brain capillaries have been used for a wide range of studies, including genomics, proteomics, functional proteomics, and cellomics 
studies (Figure 5). In addition, many techniques and methods exist to analyze isolated brain capillaries within each of these fields. Notably, 
the experimental techniques shown in Figure 5 can be used on brain capillaries isolated from a number of sources, including human, bovine, 
rodent, and porcine tissue, which may facilitate translational research. For example, Li et al. 85 studied the genomics of the blood-brain barrier 
using suppression subtractive hybridization by purifying mRNA isolated from rat brain capillaries. Additionally, Ott et a/. 86 used RT-PCR and ~RT-
PCR to study the regulation of P-gp by PXR. Many proteomic studies utilize Western blotting3 , Dot Blot analysis87 , Simple Western assar3·3 , 
ELISA88·89 , immunoprecipitation3 , and immunostaining3·90·91 . To discern transporter trafficking in the brain endothelium, Mccaffrey et a/. 9 used 
subcellular fractionation of isolated brain capillaries. Sanchez del Pino et al. 93used isolated bovine endothelial membrane vesicles to discern 
transporter location and transport direction across the blood-brain barrier. In other proteomic studies, researchers used liquid chromatography 
and tandem mass spectrometry to quantify transporter proteins94·95·96_ Functional proteomic studies have utilized transporter and leakage 
assays2·38 . Hartz et a/. 2 used zymography to determine enzyme activity in isolated brain capillaries. In addition, vast cellomic research using cell 
culture has generated numerous endothelial cell lines and models of the blood-brain barrier82·83·84 . With these models, common assays used 
include migration assays97·98 , viability and toxicity assays99 , and angiogenesis assays98 . 
Isolated brain capillaries allow for accurate characterization of protein expression and activity and description of signaling pathways at the blood-
brain barrier. This is due, in part, to the capillary content of the brain, which is only approximately 1% (v/v). Thus, usin~ whole brain homogenate 
or brain slices as a substitute for purified capillary endothelial cells will most likely result in a poor signal-to-noise ratio 4 . In addition, after 
isolation, brain capillaries are viable for at least 6 h (unpublished data from mouse and rat), which allows studies to discern specific signaling 
pathways. It is recommended to include a control group from the same preparation. 
Representative and translational models of the blood-brain barrier, such as the isolated capillary model discussed in this report, are needed 
to study barrier function in health and disease. Here we present a protocol to obtain isolated human brain capillaries at a good yield and high 
quality that can serve as an ex vivo model of the blood-brain barrier. Isolated capillaries retain their original structure and function, which allows 
using them for a number of post-isolation molecular, biochemical, and physiological assays. Care should be taken when handling human tissue 
samples, preferably in a BSL 2 or higher setting. 
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